v3.26.3
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 8 Months Ended 12 Months Ended
Jun. 30, 2026
Oct. 31, 2025
Oct. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES      
Net loss $ (5,038,000) $ (5,521,000) $ (4,705,000)
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization expense 52,000 73,000 74,000
Amortization of debt discount – Promissory notes 5,000 39,000 23,000
Gain on sale of Exotropin interests (390,000)
Change in obligation to repurchase shares 3,000 2,000
Inducement expense to convert Notes 136,000
Reserve of non-marketable securities – related party 45,000
Write-off of advances payable to former officer (221,000)
Stock-based compensation 4,930,000 4,693,000 3,853,000
Amortization of share-based compensation liability 227,000
Bad debt expense (0) (0) 9,000
Changes in operating assets and liabilities:      
Accounts receivable, net of allowance for bad debts (210,000) 159,000 (185,000)
Other receivables 3,000 9,000
Prepaid expenses 100,000 (25,000) 27,000
Inventories (422,000) (191,000) 78,000
Accounts payable and accrued expenses 158,000 200,000 (851,000)
Security deposits (18,000) 7,000
Deferred revenue 220,000 (286,000) 387,000
Net cash used in operating activities (383,000) (718,000) (1,450,000)
CASH FLOWS FROM INVESTING ACTIVITIES      
Purchase of fixed assets (78,000) (23,000)
Investment in Exotropin interests - related party (45,000)
Proceeds from sale of Exotropin interests - related party 376,000
Net cash provided by (used in) investing activities 298,000 (23,000) (45,000)
CASH FLOWS FROM FINANCING ACTIVITIES      
Payments on finance leases (21,000) (45,000) (24,000)
Shares repurchased in connection with litigation (80,000)
Proceeds from exercise of warrants 50,000
Proceeds from sale of common stock 2,150,000 300,000 500,000
Net cash provided by financing activities 2,129,000 305,000 396,000
Increase (decrease) in cash 2,044,000 (436,000) (1,099,000)
Cash at beginning of period 221,000 657,000 1,756,000
Cash at end of period 2,265,000 221,000 657,000
SUPPLEMENTAL CASH FLOW INFORMATION:      
Cash paid for taxes
Cash paid for interest 20,000 68,000
NON-CASH INVESTING AND FINANCING TRANSACTIONS:      
Reduction in royalty payable through transfer of inventory 50,000
Reduction in liability from sale of Exotropin interests 14,000
Finance lease obligations 140,000
Stock issued – Purchase of BioLumina assets 58,000
Conversion of notes payable and accrued interest for equity 514,000
Royalty payable in connection with purchase of BioLumina assets 100,000
Obligation to repurchase shares in connection with purchase of BioLumina assets 16,000
Reduction in accounts payable for equipment returned to vendor 21,000
Exchange of shares for payables $ 20,000